CDC recommends new RSV vaccine for infants under 8 months

The Centers for Disease Control and Prevention have recommended infants under eight months old get vaccinated for respiratory syncytial virus (RSV) starting in the fall. The disease is currently the "leading cause of hospitalization among infants in the U.S." Yearly, 58,000 to 80,000 children under 5 years of age, most of whom are infants, are hospitalized because of RSV. Some 100 to 300 children die from the disease every year.
The new vaccine, called nirsevimab, was approved in July. It is an antibody vaccine, which varies from typical vaccines. Regular vaccines "train the body's own immune defenses against the virus," while an antibody vaccine "works to directly fend off the virus in the body," CBS News reported. "This new RSV immunization provides parents with a powerful tool to protect their children against the threat of RSV," said CDC director Mandy Cohen. "RSV is the leading cause of hospitalizations for infants and older babies at higher risk and today we have taken an important step to make this life saving product available."
Almost all children will contract RSV by their second birthday, and the risk spikes every year in the winter and early spring months. The virus causes flu-like symptoms including fever, cough and runny nose. In children under three, "the illness may move into the lungs and cause coughing and wheezing," and in some cases "the infection turns to a severe respiratory disease," according to Cedars-Sinai. "I think that we will look back on this, in a short period of time, and see what a major impact this vote has had on the health and wellbeing of children," Dr. José Romero, director of the National Center for Immunization and Respiratory Diseases, said in a meeting for the CDC's Advisory Committee on Immunization Practices, which endorsed giving the vaccine.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Devika Rao has worked as a staff writer at The Week since 2022, covering science, the environment, climate and business. She previously worked as a policy associate for a nonprofit organization advocating for environmental action from a business perspective.
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
Oysters could help combat antibiotic resistance
Under the radar The mollusk shows infection-fighting abilities
By Devika Rao, The Week US Published
-
How Trump's executive orders are threatening scientific research
In the spotlight Agencies are purging important health information
By Devika Rao, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Sperm cells can carry past trauma in their DNA
Under the radar Your parent's past may be affecting your future
By Devika Rao, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published